Immix Biopharma | Investor Presentation Deck | 64 slides · page 45 of 64
Highlights NXC-201's lower fludarabine dose (25 mg vs 30 mg) and Carvykti's longer infusion window (5-7 days vs 5 days).
Deck · comparison_table · compare_peers · balanced density
Slide locked Sign in to view
Slide schematic 3/3
source-note 1/1 table 1/1 title 1/1
Components 3
source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.